肺癌及卵巢癌潛力靶點(diǎn)SLC34A2/NaPi2b
一、中文名稱(chēng)：肺癌及卵巢癌潛力靶點(diǎn)SLC34A2/NaPi2b相關(guān)蛋白抗體
二、產(chǎn)品描述
肺癌及卵巢癌潛力靶點(diǎn)SLC34A2/NaPi2b相關(guān)蛋白抗體，12月14日歐盟委員會(huì)（EC）將Mersana的NaPi2b ADC藥物upifitamab rilsodotin（UpRi）指定為治療卵巢癌的孤兒藥。NaPi2b靶點(diǎn)在肺癌及卵巢癌中發(fā)揮了重要作用。
三、相關(guān)產(chǎn)品
Anti-Human SLC34A2/NaPi2b Polyclonal Antibody (PHB65401)
Recombinant Human SLC34A2/NaPi2b Protein, N-His-SUMO (YHB65403)
Anti-Human SLC34A2/NaPi2b Antibody (SAA0766) (FHB65410)
Recombinant Human SLC34A2/NaPi2b Protein, N-GST (YHB65402)
Research Grade Anti-Human SLC34A2/NaPi2b (XMT-1592) (DHB65403)
Recombinant Human SLC34A2/NaPi2b, N-His (YHB65401)
Anti-Human SLC34A2/ NaPi2b Polyclonal Antibody (PHB65402)
四、產(chǎn)品詳情
名稱(chēng)：Anti-SLC34A2/NaPi2b Polyclonal Antibody (PHB65401)
別名：NaPi2b,Sodium/phosphate cotransporter 2B, Na(+)-dependent phosphate cotransporter 2B, Na(+)/Pi cotransporter 2B, Sodium-dependent phosphate transport protein 2B, NaPi3b, NaPi-2b, SLC34A2, Solute carrier family 34 member 2, Sodium-phosphate transport protein 2B，SLC34A2蛋白抗體，NaPi2b蛋白抗體
貨號(hào)：PHB65401
種屬反應(yīng)性：Human, Rat
宿主：Rabbit
同種型：IgG
克隆類(lèi)型：Polyclonal
免疫原：E. coli - derived recombinant Human SLC34A2/NaPi2b (Ser251-Asp361).
經(jīng)測(cè)試應(yīng)用：ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
靶標(biāo)：Sodium/phosphate cotransporter 2B, Na(+)-dependent phosphate cotransporter 2B, Na(+)/Pi cotransporter 2B, Sodium-dependent phosphate transport protein 2B, NaPi3b, NaPi-2b, SLC34A2, Solute carrier family 34 member 2, Sodium-phosphate transport protein 2B
純化方式：Purified by antigen affinity column.
Accession號(hào)：O95436
應(yīng)用：ELISA, IHC, WB
狀態(tài)：Liquid
保存溶液：0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
穩(wěn)定性和存儲(chǔ)：Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. (PHB65401)
SLC34A2 promotes cancer proliferation and cell cycle progression by targeting TMPRSS3 in colorectal cancer. PMID: 34929599
The role of SLC34A2 in intestinal phosphate absorption and phosphate homeostasis. PMID: 30343332
Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma. PMID: 30592329
Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases. PMID: 34944522
SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms. PMID: 32005974
The SLC34A2-ROS-HIF-1-induced up-regulation of EZH2 expression promotes proliferation and chemo-resistance to apoptosis in colorectal cancer. PMID: 30038060
New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review. PMID: 37259144
SLC34A2 Gene mutation of pulmonary alveolar microlithiasis: report of four cases and review of literatures. PMID: 23164546
Impaired phosphate transport in SLC34A2 variants in patients with pulmonary alveolar microlithiasis. PMID: 35443721
SLC34A2 promotes neuroblastoma cell stemness via enhancement of miR-25/Gsk3beta-mediated activation of Wnt/beta-catenin signaling. PMID: 30868061
SLC34A2 promotes cell proliferation by activating STX17-mediated autophagy in esophageal squamous cell carcinoma. PMID: 38720472
SLC34A2 Targets in Calcium/Phosphorus Homeostasis of Mammary Gland and Involvement in Development of Clinical Mastitis in Dairy Cows. PMID: 38731279
Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion. PMID: 28281971
Constitutive depletion of Slc34a2/NaPi-IIb in rats causes perinatal mortality. PMID: 33846411
SLC34A2 regulates miR-25-Gsk3beta signaling pathway to affect tumor progression in gastric cancer stem cell-like cells. PMID: 29178392
Is SLC34A2 Associated With Concomitant Calcium Metabolism Disorder in Pulmonary Alveolar Microlithiasis (PAM)? PMID: 37217383
SLC34A2 Up-regulation And SLC4A4 Down-regulation Correlates With Invasion, Metastasis, And The MAPK Signaling Pathway In Papillary Thyroid Carcinomas. PMID: 34405007
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. PMID: 35437317
Eight novel variants in the SLC34A2 gene in pulmonary alveolar microlithiasis. PMID: 31831582
SLC34A2 Regulates the Proliferation, Migration, and Invasion of Human Osteosarcoma Cells Through PTEN/PI3K/AKT Signaling. PMID: 28777670
CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations. PMID: 38070598
Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity. PMID: 28151475
NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort. PMID: 34953676
Antibody-Drug Conjugates in Gynecologic Cancer. PMID: 37229642
(213)Bi/(211)At-Labeled MX35, an anti-sodium-dependent phosphate transport protein 2b (NaPi2b) murine monoclonal antibody. PMID: 22675742
Toward a Topology-Based Therapeutic Design of Membrane Proteins: Validation of NaPi2b Topology in Live Ovarian Cancer Cells. PMID: 35911971
Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer. PMID: 34504954
Development of potent non-acylhydrazone inhibitors of intestinal sodium-dependent phosphate transport protein 2b (NaPi2b). PMID: 35917765
Design, synthesis and biological evaluation of novel pyridine derivatives as gut-selective NaPi2b inhibitors. PMID: 35346844
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. PMID: 30158152
Discovery of Gut-Restricted Small-Molecule Inhibitors of Intestinal Sodium-Dependent Phosphate Transport Protein 2b (NaPi2b) for the Treatment of Hyperphosphatemia. PMID: 35034442
Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b. PMID: 18724815
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. PMID: 32534811
Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues. PMID: 21956469
The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer. PMID: 19300415
In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35. PMID: 22553815
Advances in antibody-drug conjugates for gynecologic malignancies. PMID: 36484278
詳情請(qǐng)咨詢(xún)Antibodysystem中國(guó)授權(quán)總代理-武漢佰樂(lè)博生物技術(shù)有限公司
網(wǎng)址：https://www.antibodysystem.com/product/16940.html
武漢佰樂(lè)博生物技術(shù)有限公司作為法國(guó)Antibodysystem品牌亞洲區(qū)授權(quán)總代理。提供近3萬(wàn)種蛋白、抗體等核心生命科學(xué)試劑，旨在為生命科學(xué)科研工作者提供專(zhuān)業(yè)、全面、可靠的試劑產(chǎn)品。
試劑 | 耗材 | 定制 | 實(shí)驗(yàn)服務(wù) | 供應(yīng)鏈
免費(fèi)熱線(xiàn)：027-65279366 /18108604356